Research out of the University of New Hampshire shows that communities that were easier for people to lace up and get out for a walk during the COVID-19 pandemic also helped lower the impact of mental health issues, like stress and anxiety.

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease progression in patients with advanced triple-negative breast cancer (TNBC), one of the most aggressive and hard-to-treat forms of breast cancer.

A team of researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has successfully treated a rare and aggressive T-cell lymphoma that developed after CAR T-cell therapy for multiple myeloma, marking a first in the field of hematologic cancer research. The findings were published in the August 21 issue of the New England Journal of Medicine.

Why do people infected with the human immunodeficiency virus (HIV) often suffer from cardiovascular, liver, and other comorbidities? Researchers at the Centre for Individualised Infection Medicine (CiiM) investigated this question as part of the 2000HIV study, a multi-omics cohort coordinated by several research centers in the Netherlands. They identified various molecules and mechanisms that could be linked to the development of these comorbidities. The scientists are making the extensive results of their study freely available. They hope that they will be used for new research approaches and lead to a better understanding of the underlying causes and to helpful therapies. The researchers have now published their study results in the journal Nature Medicine. The CiiM is a joint institution of the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH).